Literature DB >> 2679444

[Treatment of endometriosis].

L Kiesel1, K Bertges, T R von Holst, B Runnebaum.   

Abstract

In a randomized study, the effect of gestrinone (2 x 2.5 mg/week) was compared with the effect of danazol (3 x 200 mg/day) in treating 30 patients with laparoscopically proven endometriotic implants for 6 months. Therapy was effective in 80%-90% of cases and pregnancy rates were similar, but the incidence of side effects was different in the groups. In addition, buserelin (900 micrograms/day intranasally) was investigated in a multinational, multicenter trial in 275 patients. In 80%, GnRH agonist treatment induced the disappearance or reduction of endometriotic implants. The main side effects were due to estrogenic suppression. Presently, various methods of hormonal treatment are under investigation, especially to determine recurrency rates of endometriosis and long-term side effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2679444     DOI: 10.1007/bf02417628

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  10 in total

1.  [Initial results in the treatment of endometriosis with the LH-RH analog buserelin].

Authors:  W Hardt; M Schmidt-Gollwitzer; K Schmidt-Gollwitzer; T Genz; J Nevinny-Stickel
Journal:  Geburtshilfe Frauenheilkd       Date:  1986-08       Impact factor: 2.915

2.  Stimulation of luteinizing hormone release and cyclic nucleotide production by arachidonic acid in cultured pituitary gonadotrophs.

Authors:  L Kiesel; K J Catt
Journal:  Neuroendocrinology       Date:  1987-06       Impact factor: 4.914

3.  Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.

Authors:  M R Henzl; S L Corson; K Moghissi; V C Buttram; C Berqvist; J Jacobson
Journal:  N Engl J Med       Date:  1988-02-25       Impact factor: 91.245

4.  Gonadotropin releasing hormone enhances polyphosphoinositide hydrolysis in rat pituitary cells.

Authors:  L Kiesel; K Bertges; T Rabe; B Runnebaum
Journal:  Biochem Biophys Res Commun       Date:  1986-01-29       Impact factor: 3.575

5.  [Gonadotropin-releasing hormone receptors in human breast cancer tissue].

Authors:  L Kiesel; M Kaufmann; F Haeseler; K Klinga; T von Holst; W Schmidt; B Runnebaum
Journal:  Geburtshilfe Frauenheilkd       Date:  1988-06       Impact factor: 2.915

6.  [Metabolic effects and general side effects in the treatment of endometriosis with an LHRH agonist].

Authors:  U Cirkel; K W Schweppe; H Ochs; H P Schneider
Journal:  Geburtshilfe Frauenheilkd       Date:  1987-03       Impact factor: 2.915

7.  Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.

Authors:  A Lemay; R Maheux; N Faure; C Jean; A T Fazekas
Journal:  Fertil Steril       Date:  1984-06       Impact factor: 7.329

8.  Combined (hormonal and microsurgical) therapy in infertile women with endometriosis.

Authors:  J Donnez; M Lemaire-Rubbers; Y Karaman; M Nisolle-Pochet; F Casanas-Roux
Journal:  Fertil Steril       Date:  1987-08       Impact factor: 7.329

9.  The response of human endometriotic implants to the anti-progesterone steroid R 2323: a histologic and ultrastructural study.

Authors:  F J Cornillie; G Vasquez; I Brosens
Journal:  Pathol Res Pract       Date:  1985-12       Impact factor: 3.250

10.  A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis.

Authors:  A M Dlugi; S Rufo; J F D'Amico; M M Seibel
Journal:  Fertil Steril       Date:  1988-05       Impact factor: 7.329

  10 in total
  1 in total

1.  Laparoscopic colorectal resection for endometriosis.

Authors:  R Campagnacci; S Perretta; M Guerrieri; A M Paganini; A De Sanctis; A Ciavattini; E Lezoche
Journal:  Surg Endosc       Date:  2005-03-11       Impact factor: 4.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.